NAS · US · cero.bio
0.0030USDMkt Cap: —P/E: —Last update: 2026-05-19
CERo Therapeutics Holdings, Inc., an immunotherapy company, engages in the development of engineered T cell therapeutics for the treatment of cancer. The company's lead development candidate is CER-1236, an autologous T …
loading…
Indicators:|
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)—
Gross Profit-605.42K USD
Net Income (TTM)-19.92M USD
Revenue/Share—
Last Price0.0030 USD
Fiscal Year End—
MR Quarter—
Employees8
CountryUS
Sector—
Industry—
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-0.01
EPS (TTM)—
EPS (Forward)—
52W Range
—
52W High0.0030 USD
52W Low0.0030 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE365.75%
ROA-547.09%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-16.08M USD
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt-259.14K USD
Net Debt/EBITDA0.01
Balance Sheet
Debt/Equity-0.13
Current Ratio0.14
Quick Ratio0.08
Book Value/Sh-0.4580 USD
Cash/Share0.0190 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float43.14M
Insiders—
Institutions—
Technical
SMA 50—
SMA 200—
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)10.00K
Avg Vol (10d)—
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—